A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Trial Profile

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Enfortumab vedotin (Primary)
  • Indications Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Agensys
  • Most Recent Events

    • 06 Jun 2017 Results (n=68,data cut off; 3 Jan 2017) assessing tolerability presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2017 Results (n=81) from this trial published in a Seattle Genetics Media Release.
    • 05 Jun 2017 According to a Seattle Genetics media release, data from this trial presented at the 2017 ASCO Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top